Why the study?
What are the pharmacodynamics, pharmacokinetics, and safety of dofetilide in healthy volunteers?
What are the pharmacodynamics, pharmacokinetics, and safety of dofetilide in healthy volunteers?
Dofetilide demonstrates selective class III antiarrhythmic activity with dose-dependent QTc prolongation and high oral bioavailability in healthy volunteers.
No takes yet. Share an insight, caveat, or question.
Supports QTc monitoring at oral dofetilide initiation; confirms high bioavailability for arrhythmia trials.
Tham et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: